Advertisement

Advertisement

ATYR Stock Latest News

aTyr Pharma Regains Global Rights to Efzofitimod

Company AnnouncementsaTyr Pharma Regains Global Rights to Efzofitimod

aTyr Pharma Lawsuit: Company Asks Court to Dismiss Investor Securities Claims

PremiumClass Action

aTyr Pharma Lawsuit: Company Asks Court to Dismiss Investor Securities Claims

7d ago

Joseph Pantginis Reiterates Hold as Efzofitimod Shifts to Restrictive Lung Phenotype After Mixed Phase 3 EFZO-FIT Results

PremiumRatings

Joseph Pantginis Reiterates Hold as Efzofitimod Shifts to Restrictive Lung Phenotype After Mixed Phase 3 EFZO-FIT Results

19d ago

aTyr Pharma Granted Nasdaq Extension to Regain Compliance

PremiumCompany Announcements

aTyr Pharma Granted Nasdaq Extension to Regain Compliance

2M ago

Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis

PremiumCompany Announcements

Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis

2M ago

aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data

PremiumCompany AnnouncementsaTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data

2M ago

aTyr Pharma upgraded to Buy from Hold at Freedom Broker

The Fly

aTyr Pharma upgraded to Buy from Hold at Freedom Broker

3M ago

aTyr Pharma Inc options imply 30.5% move in share price post-earnings

The Fly

aTyr Pharma Inc options imply 30.5% move in share price post-earnings

3M ago

Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports

PremiumThe Fly

Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports

3M ago

aTyr Pharma reports Q1 EPS (11c), consensus (15c)

PremiumThe Fly

aTyr Pharma reports Q1 EPS (11c), consensus (15c)

3M ago

Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program

PremiumRatings

Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program

3M ago

Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss

PremiumRatings

Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss

3M ago

aTyr Pharma provides regulatory update on efzofitimod following Type C meeting

PremiumThe FlyaTyr Pharma provides regulatory update on efzofitimod following Type C meeting

3M ago

aTyr Pharma Announces New Phase 3 Sarcoidosis Trial

Company Announcements

aTyr Pharma Announces New Phase 3 Sarcoidosis Trial

3M ago

ATYR Upcoming Earnings Report: What to Expect?

Pre-Earnings

ATYR Upcoming Earnings Report: What to Expect?

3M ago

aTyr Pharma Inc options imply 14.1% move in share price post-earnings

PremiumThe Fly

aTyr Pharma Inc options imply 14.1% move in share price post-earnings

3M ago

Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation

PremiumCompany Announcements

Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation

5M ago

aTyr Pharma reports Q4 EPS (14c), consensus (17c)

PremiumThe Fly

aTyr Pharma reports Q4 EPS (14c), consensus (17c)

5M ago

aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod

PremiumThe Fly

aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod

6M ago

aTyr Pharma Receives Nasdaq Deficiency Notice

PremiumCompany AnnouncementsaTyr Pharma Receives Nasdaq Deficiency Notice

8M ago

aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns

Market News

aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns

8M ago

aTyr Pharma Reports Increased Losses Amid Rising R&D Costs

Company Announcements

aTyr Pharma Reports Increased Losses Amid Rising R&D Costs

9M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >